Qvar Redihaler Patent Expiration

Qvar Redihaler is a drug owned by Norton Waterford Ltd. It is protected by 18 US drug patents filed from 2017 to 2024. Out of these, 16 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 19, 2041. Details of Qvar Redihaler's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583643 Inhalers and related methods
Aug, 2041

(16 years from now)

Active
US11957832 Breath actuated inhaler
May, 2041

(16 years from now)

Active
US11559637 Inhalers and related methods
Jul, 2039

(14 years from now)

Active
US10792447 Breath actuated inhaler
Jan, 2039

(14 years from now)

Active
US11865247 Inhalers and related methods
Jan, 2038

(13 years from now)

Active
US11395888 Inhalers and related methods
Jan, 2038

(13 years from now)

Active
US11896759 Inhalers and related methods
Jan, 2038

(13 years from now)

Active
US11793953 Inhalers and related methods
Jan, 2038

(13 years from now)

Active
US10561808 Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Active
US8931476 Inhaler
Jul, 2031

(6 years from now)

Active
US11395889 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US10022510 Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

Active
US10022509 Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

Active
US10086156 Dose counter for inhaler and method for counting doses
May, 2031

(6 years from now)

Active
US10695512 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US8132712 Metered-dose inhaler
Sep, 2028

(3 years from now)

Active
US7637260 Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber
Aug, 2020

(4 years ago)

Expired
US6446627 Inhaler dose counter
Dec, 2017

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qvar Redihaler's patents.

Given below is the list of recent legal activities going on the following patents of Qvar Redihaler.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 21 Mar, 2024 US10792447
Recordation of Patent Grant Mailed 13 Feb, 2024 US11896759
Recordation of Patent eGrant 13 Feb, 2024 US11896759
Email Notification 13 Feb, 2024 US11896759
Patent Issue Date Used in PTA Calculation 13 Feb, 2024 US11896759
Patent eGrant Notification 13 Feb, 2024 US11896759
Mail Patent eGrant Notification 13 Feb, 2024 US11896759
Email Notification 25 Jan, 2024 US11896759
Issue Notification Mailed 24 Jan, 2024 US11896759
Dispatch to FDC 16 Jan, 2024 US11896759


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Qvar Redihaler and ongoing litigations to help you estimate the early arrival of Qvar Redihaler generic.

Qvar Redihaler's Litigations

Qvar Redihaler been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Qvar Redihaler's patents.

Last updated on November 12, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10561808 October, 2018 Decision
(20 Sep, 2019)
Declan Walsh et al.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Qvar Redihaler is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qvar Redihaler's family patents as well as insights into ongoing legal events on those patents.

Qvar Redihaler's Family Patents

Qvar Redihaler has patent protection in a total of 27 countries. It's US patent count contributes only to 15.8% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Qvar Redihaler.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Qvar Redihaler's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 19, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Qvar Redihaler Generics:

There are no approved generic versions for Qvar Redihaler as of now.

Alternative Brands for Qvar Redihaler

There are several other brand drugs using the same active ingredient (Beclomethasone Dipropionate) as Qvar Redihaler. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Teva Branded Pharm
Qnasl
Qvar 40
Qvar 80






About Qvar Redihaler

Qvar Redihaler is a drug owned by Norton Waterford Ltd. Qvar Redihaler uses Beclomethasone Dipropionate as an active ingredient. Qvar Redihaler was launched by Norton Waterford in 2017.

Approval Date:

Qvar Redihaler was approved by FDA for market use on 03 August, 2017.

Active Ingredient:

Qvar Redihaler uses Beclomethasone Dipropionate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate ingredient

Dosage:

Qvar Redihaler is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.04MG/INH AEROSOL, METERED Prescription INHALATION
0.08MG/INH AEROSOL, METERED Prescription INHALATION